Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05280548 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
A Phase 3 study of Fabry Disease, sponsored by Sanofi.
- Active
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT05280548: Active Phase 3 study of Fabry Disease, sponsored by Sanofi.
NCT05280548 is a Phase 3 study of Fabry Disease that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 104 participants, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05280548, a Phase 3 study of Fabry Disease, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy. * Study visits will take place approximately every 3 to 6 months * Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 45 months with the total study duration up to 5.3 years maximum.
Conditions Studied
Interventions
- DRUG Venglustat (GZ402671)
- DRUG Agalsidase alfa
- DRUG Agalsidase beta (GZ419828)
- DRUG Migalastat
Study Locations (20)
Other
- Investigational Site Number : 0400001 - Graz
- Investigational Site Number : 1560002 - Beijing
- Investigational Site Number : 1560005 - Beijing
- Investigational Site Number : 1560001 - Chengdu
- Investigational Site Number : 1560007 - Guangzhou
- Investigational Site Number : 1560003 - Shanghai
- Investigational Site Number : 2030001 - Prague
- Investigational Site Number : 2080001 - Copenhagen
Alberta
- Investigational Site Number : 1240003 - Calgary
- Investigational Site Number : 1240006 - Edmonton
Alabama
- University of Alabama -The Kirklin Clinic- Site Number : 8400010 - Birmingham
California
- University of California Los Angeles Medical Center- Site Number : 8400008 - Los Angeles
Georgia
- Emory University School of Medicine - Atlanta- Site Number : 8400009 - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005 - Chicago
New York
- Maryam Banikazemi, MD- Site Number : 8400001 - Hawthorne
Texas
- Renal Disease Research Institute- Site Number : 8400012 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2027-12-06 |
| Phase | Phase 3 |
What the registry record for NCT05280548 still lists
NCT05280548 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Fabry Disease appearing as the primary indexed condition, and to 4 interventions - of which Venglustat (GZ402671) is the first listed.
NCT05280548 names 20 study sites across 12 states, led by Other, Alberta, Alabama.
Frequently Asked Questions
What is clinical trial NCT05280548 about?
NCT05280548 is a clinical study titled "A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease". This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LV...
What is the current status of trial NCT05280548?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2022-05-03. Estimated completion is 2027-12-06.
What conditions does trial NCT05280548 study?
This clinical trial studies the following conditions: Fabry Disease.
What interventions are being tested in trial NCT05280548?
The interventions under investigation include: Venglustat (GZ402671) (DRUG), Agalsidase alfa (DRUG), Agalsidase beta (GZ419828) (DRUG), Migalastat (DRUG).
Who is sponsoring clinical trial NCT05280548?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05280548 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05280548's enrollment target sits among peer trials
104 7th of 32 higher than 26 of 32 other Fabry Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fabry Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
ACTIVE NOT RECRUITING · Phase 3
-
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
ACTIVE NOT RECRUITING · Phase 3
-
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI